Piper Sandler Cuts Biogen (NASDAQ:BIIB) Price Target to $115.00
Biogen (NASDAQ:BIIB – Free Report) had its target price cut by Piper Sandler from $135.00 to $115.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock. A number of other research analysts have also recently weighed in on BIIB. BMO Capital Markets cut […]
Biogen (NASDAQ:BIIB – Free Report) had its target price cut by Piper Sandler from $135.00 to $115.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock. A number of other research analysts have also recently weighed in on BIIB. BMO Capital Markets cut […]
